glp-1 drugs and dementia Advances in Clinical Experimental Medicine GLP-1s and Reduced Risk of

Engineering of a GLP-1 Analogue Peptide/Anti-PCSK9 Antibody Fusion for Type 2 Diabetes Treatment

Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability

While its too early to draw definitive conclusions, the alcohol industry may already be on the cusp of a transformation

All dosing figures describe the documented research/trial protocol under a strict research-use-only framing

In a study using cultured rat hippocampal neurons, pre-treatment of nerve cells with GLP-1 resulted in a weakened Ca 2+ response to glutamate and weakened membrane depolarization ( Effects on Parkinsons Disease Parkinsons disease (PD) is a chronic neurodegenerative disease that affects the central nervous system and the second most common neurodegenerative disease after AD (56)

It is important to consider the potential confounding effects of concurrent glucose reduction with DPP4 inhibitors when analyzing preclinical investigations